Customs Valuation for IMPs and Clinical Material in the US and Europe

When biotech and pharma companies transport investigational medicinal products (IMPs) internationally, they are often required to pay import fees. Understanding customs valuation for IMPs and clinical material in the US and Europe will put you ahead of the game.

These taxes are based on the shipment’s value; however, determining that value can be challenging. Paradoxically, while the investigational medicinal products (IMPs) are not actually being sold, governments consider each shipment a sale.  As always, the goal is to value these items accurately – estimating too high can increase a company’s customs obligation, and estimating too low can have short- and long-term tax ramifications. To further complicate matters, every country has a different tax rate.

Download our white paper below to learn how to effectively calculate IMP and clinical material valuation and the impact of using these valuations within the US and Europe.

We provide a complete range of clinical supply services and we are committed to supporting clients at every stage of the clinical cycle, delivering best-in-class services efficiently and effectively.

Find out more about our Clinical Trial Services here


Our dedicated team of specialists will be happy to discuss any of your Pharmaceutical Development needs. Contact us on +1 779-208-1819 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pciservices.com

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients